Cannabinoid Receptor Meditating Compounds for Metabolic Disease


There is evidence that the metabolic effects of endocannabinoids are mediated by CB1 receptors in peripheral tissues. While prior attempts at generating CB1 receptor blockers have had serious neuropsychiatric side effects, inventors at NIH have discovered compounds that block CB1 receptors with reduced brain penetrance. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinas. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including liver or kidney fibrosis, without the dangerous the side effects.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of metabolic disease and related conditions such as diabetes, obesity and fibrotic disease.
 
  • Cannabinoid receptor blockers with reduced brain penetrance relative to older drugs of this class, also having secondary target for improved therapeutic efficacy.


Development Stage:
Early-stage

Related Invention(s):
E-211-2006/0
E-282-2012/0
E-103-2013/0


Inventors:

George Kunos (NIAAA)  ➽ more inventions...

Malliga Iyer (NIAAA)  ➽ more inventions...

Resat Cinar (NIAAA)  ➽ more inventions...

Kenner Rice (NIDA)  ➽ more inventions...


Intellectual Property:
US Application No. 15/309,728
US Application No. 61/991,333
PCT Application No. PCT/US2015/029946

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-140-2014/0
Updated: Aug 23, 2017